“The fact that the Fosamax litigation is moving forward is a hopeful sign for patients who have been injured by this drug,” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP.
(PRWEB) March 05, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is informing consumers that Merck will be going to trial later this month over lawsuits alleging its bone loss drug, Fosamax, caused femur fractures. The case going to trial in New Jersey Superior Court is Su v. Merck Sharp & Dohme Corp., case number ATL-L-0789-11, in the Superior Court of New Jersey, Atlantic County. According to Law 360, the lawsuit going to trial is one of 2,000 similar cases in New Jersey.
“The fact that the Fosamax litigation is moving forward is a hopeful sign for patients who have been injured by this drug,” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP. “One of our cases is among those being considered for trial; in addition, we represent several hundred clients in filed lawsuits concerning Fosamax.” The firm offers free legal advice for patients who suffered femur fractures or jaw injuries after taking Fosamax.
Law 360 reports that jury selection is scheduled to begin on March 11. The Plaintiff in the lawsuit going to trial in New Jersey is Christina Su, a New Jersey resident who took Fosamax between July 2003 and February 2009, when she suffered a fracture in her right femur. About six months later, she suffered another fracture in her left femur that required insertion of a rod in her leg, the suit alleges. Su claims that Merck failed to warn about the risks associated with the bone loss drug.
According to Reuters, last month jurors in Manhattan ordered Merck to pay $285,000 to the Plaintiff, ruling that the company failed to warn about the risks of drug (Scheinberg v. Merck & Co, Inc., U.S. District Court, Southern District of New York, 09-4119).
Fosamax and other bisphosphonate drugs are approved to fight bone loss from conditions such as osteoporosis. However, the drug has come under fire due to reports that it is linked to an increased risk of femur fractures. In June, the Archives of Internal Medicine published a study comparing the atypical versus “classic” fractures. The researchers found a significant relationship between bisphosphonate use and atypical femur fractures, reporting that 82 percent of the patients in the atypical fracture group had taken bisphosphonates.
In 2010, the U.S. Food and Drug Administration (FDA) updated the safety information on Fosamax to warn about the risk of atypical femur fractures. The agency has also published a review in The New England Journal of Medicine suggesting that there is little benefit of taking bisphosphonates for longer than five years. The findings were based on trials involving 2,342 postmenopausal women.
Parker Waichman LLP continues to offer free legal consultations to victims of Fosamax side effects. If you or a loved experienced an atypical femur fracture and you believe Fosamax is to blame, please contact their office by visiting the firm’s Fosamax website. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney